2nd Quarter - Report

THE MCMANUS GROUP for EMD SERONO, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALANNA TEMME LD, Rep. Jon Porter
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1339 (118th), S. 127 (118th), S. 1967 (118th), H.R. 3561 (118th), H.R. 4507 (118th)

Medicare/Medicaid MMM

Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALANNA TEMME —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023

LobbyistCovered position, as disclosed
LAWREN D GEER —
JOHN MCMANUS —
ALANNA TEMME —
ALEX WHALEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2673 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.